Few differences were found for cardiovascular, kidney, and mortality outcomes between liraglutide, semaglutide, and dulaglutide for patients with type 2 diabetes.
GLP-1–pathway agonists such as semaglutide and newer multi-agonists have transformed care for obesity and diabetes, yet developers still wrestle with durability, tissue targeting, and signal "bias." ...
PHILADELPHIA.Today on MSN
Wistar to Honor Dr. Svetlana Mojsov Whose Discovery of GLP-1 Protein is Behind Blockbuster Weight-Loss Drugs
The Wistar Institute honors Svetlana Mosjov, Ph.D., as the 2025 Helen Dean King Award recipient. Dr. Mojsov, research ...
Now that millions of people have taken weight loss medications like Wegovy, what have we learned? Coming up at 9 a.m. on ...
Over a dozen phase 3 trials for generic semaglutide are underway in China, setting the stage for one of the world’s largest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback